BioCentury | Nov 16, 2015
Emerging Company Profile

Bridge to POC

...or collaborating with other companies," said CEO Haishan Jang. Jang was senior director at J&J's Centocor...
BioCentury | Jun 16, 2014
Finance

Biotech rating scheme

...2013: Chairman and CEO of Coronado Biosciences Inc. (NASDAQ:CNDO); 1990-2012: Johnson & Johnson (NYSE:JNJ) and Centocor Inc....
BioCentury | Sep 30, 2013
Clinical News

Simponi golimumab regulatory update

...over a dispute related to a 1998 deal between J&J's Janssen Biotech Inc. unit (formerly Centocor...
BioCentury | Aug 12, 2013
Finance

Abiding no more

...to Gansu Duyiwei Biotechnology Co. Ltd. Apexigen also has deals to create mAbs for the Centocor...
BioCentury | Aug 5, 2013
Clinical News

Simponi golimumab regulatory update

...over a dispute related to a 1998 deal between J&J's Janssen Biotech Inc. unit (formerly Centocor...
BioCentury | May 20, 2013
Clinical News

Simponi golimumab regulatory update

...over a dispute related to a 1998 deal between J&J's Janssen Biotech Inc. unit (formerly Centocor...
BioCentury | May 20, 2013
Company News

Aveo Pharmaceuticals, J&J deal

...Aveo disclosed in a 10-Q filing that Johnson & Johnson's Janssen Biotech Inc. (formerly Centocor Ortho...
BioCentury | Jul 23, 2012
Clinical News

Simponi golimumab regulatory update

...over a dispute related to a 1998 deal between J&J's Janssen Biotech Inc. unit (formerly Centocor...
BioCentury | Jun 28, 2012
Targets & Mechanisms

Fragmentary progress in endometriosis

...2008, researchers from University Hospitals Leuven, the University of Oxford and Johnson & Johnson 's Centocor Inc....
BioCentury | Jun 18, 2012
Clinical News

Simponi golimumab: Phase III data

...over a dispute related to a 1998 deal between J&J's Janssen Biotech Inc. unit (formerly Centocor...
Items per page:
1 - 10 of 860
BioCentury | Nov 16, 2015
Emerging Company Profile

Bridge to POC

...or collaborating with other companies," said CEO Haishan Jang. Jang was senior director at J&J's Centocor...
BioCentury | Jun 16, 2014
Finance

Biotech rating scheme

...2013: Chairman and CEO of Coronado Biosciences Inc. (NASDAQ:CNDO); 1990-2012: Johnson & Johnson (NYSE:JNJ) and Centocor Inc....
BioCentury | Sep 30, 2013
Clinical News

Simponi golimumab regulatory update

...over a dispute related to a 1998 deal between J&J's Janssen Biotech Inc. unit (formerly Centocor...
BioCentury | Aug 12, 2013
Finance

Abiding no more

...to Gansu Duyiwei Biotechnology Co. Ltd. Apexigen also has deals to create mAbs for the Centocor...
BioCentury | Aug 5, 2013
Clinical News

Simponi golimumab regulatory update

...over a dispute related to a 1998 deal between J&J's Janssen Biotech Inc. unit (formerly Centocor...
BioCentury | May 20, 2013
Clinical News

Simponi golimumab regulatory update

...over a dispute related to a 1998 deal between J&J's Janssen Biotech Inc. unit (formerly Centocor...
BioCentury | May 20, 2013
Company News

Aveo Pharmaceuticals, J&J deal

...Aveo disclosed in a 10-Q filing that Johnson & Johnson's Janssen Biotech Inc. (formerly Centocor Ortho...
BioCentury | Jul 23, 2012
Clinical News

Simponi golimumab regulatory update

...over a dispute related to a 1998 deal between J&J's Janssen Biotech Inc. unit (formerly Centocor...
BioCentury | Jun 28, 2012
Targets & Mechanisms

Fragmentary progress in endometriosis

...2008, researchers from University Hospitals Leuven, the University of Oxford and Johnson & Johnson 's Centocor Inc....
BioCentury | Jun 18, 2012
Clinical News

Simponi golimumab: Phase III data

...over a dispute related to a 1998 deal between J&J's Janssen Biotech Inc. unit (formerly Centocor...
Items per page:
1 - 10 of 860